)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Rani Therapeutics Holdings (RANI) investor relations material
Rani Therapeutics Holdings Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Focused on developing oral delivery technology for biologics, with no approved products or commercial revenue to date.
RaniPill platform includes RaniPill GO (up to 3mg) and RaniPill HC (up to 200μL), with preclinical and Phase 1 trials completed for GO and clinical testing for HC planned in H2 2025.
Entered collaborations with Chugai and ProGen for evaluation and co-development of oral therapeutics, including a strategic research partnership with Chugai for two molecules.
Presented preclinical data showing oral RT-114 (GLP-1/GLP-2 agonist) bioequivalent to subcutaneous delivery, supporting the obesity treatment pipeline.
Substantial doubt exists regarding ability to continue as a going concern due to limited cash and ongoing losses.
Financial highlights
Net loss for Q2 2025 was $11.2M, a 16% improvement compared to Q2 2024; net loss for H1 2025 was $24.0M, down 14.8% year-over-year.
Operating expenses for Q2 2025 were $10.5M, down 16.1% from Q2 2024, driven by lower R&D and G&A costs.
Cash, cash equivalents, and marketable securities totaled $10.2M as of June 30, 2025, down from $27.6M at year-end 2024.
Contract revenue of $0.2M recognized in H1 2025 from Chugai evaluation agreement.
Net cash used in operating activities was $13.9M for H1 2025, compared to $18.4M in H1 2024.
Outlook and guidance
Existing capital resources, including recent $3M equity raise, are insufficient to initiate pivotal clinical trials.
Management anticipates current cash will not meet operating needs beyond late September 2025 without additional funding.
Board is reviewing strategic alternatives and financing options; failure to secure funding may result in liquidation or bankruptcy.
Phase 1 clinical trial of RT-114 for obesity expected to begin in the second half of 2025.
Management remains focused on advancing the oral biologics pipeline and leveraging strategic collaborations.
Explain the Chugai collaboration's impact.
Why did R&D expenses decrease?
When is the RT-114 Phase 1 trial expected?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Rani Therapeutics Holdings earnings date
Q3 20257 Nov, 2025
Next Rani Therapeutics Holdings earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company primarily focused on the development of innovative technologies for the oral delivery of biologics. The company's flagship technology, the RaniPill capsule, represents a novel, proprietary platform designed to administer biologic drugs orally that would typically be delivered via injection. This technology aims to improve patient outcomes by making treatment more accessible and less invasive. Rani Therapeutics is exploring the potential of its platform across a range of drug substances, including peptides, proteins, and antibodies, with applications in various therapeutic areas. The company is headquartered in San Jose, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage